Please use this identifier to cite or link to this item:
Title: Could MicroRNAs be useful tools to improve the diagnosis and treatment of rare gynecological cancers? A brief overview
Authors: Di Fiore, Riccardo
Suleiman, Sherif
Pentimalli, Francesca
O’Toole, Sharon A.
O’Leary, John J.
Ward, Mark P.
Conlon, Neil T.
Sabol, Maja
Ozretic, Petar
Erson-Bensan, Ayse Elif
Reed, Nicholas
Giordano, Antonio
Herrington, Simon
Calleja-Agius, Jean
Keywords: MicroRNA
Gynecology -- Diagnosis
Cancer -- Treatment
Vagina -- Cancer
Generative organs -- Cancer
Issue Date: 2021
Publisher: MDPI
Citation: Di Fiore, R., Suleiman, S., Pentimalli, F., O’Toole, S. A., O’Leary, J. J., Ward M. P.,…Calleja-Agius, J. (2021). Could MicroRNAs be useful tools to improve the diagnosis and treatment of rare gynecological cancers? A brief overview. International Journal of Molecular Sciences, 22, 3822.
Abstract: Gynecological cancers pose an important public health issue, with a high incidence among women of all ages. Gynecological cancers such as malignant germ-cell tumors, sex-cord-stromal tumors, uterine sarcomas and carcinosarcomas, gestational trophoblastic neoplasia, vulvar carcinoma and melanoma of the female genital tract, are defined as rare with an annual incidence of <6 per 100,000 women. Rare gynecological cancers (RGCs) are associated with poor prognosis, and given the low incidence of each entity, there is the risk of delayed diagnosis due to clinical inexperience and limited therapeutic options. There has been a growing interest in the field of microRNAs (miRNAs), a class of small non-coding RNAs of 22 nucleotides in length, because of their potential to regulate diverse biological processes. miRNAs usually induce mRNA degradation and translational repression by interacting with the 30 untranslated region (30-UTR) of target mRNAs, as well as other regions and gene promoters, as well as activating translation or regulating transcription under certain conditions. Recent research has revealed the enormous promise of miRNAs for improving the diagnosis, therapy and prognosis of all major gynecological cancers. However, to date, only a few studies have been performed on RGCs. In this review, we summarize the data currently available regarding RGCs.
Appears in Collections:Scholarly Works - FacM&SAna

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.